Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.


Hier finden Sie die neuesten Informationen und Nachrichten. So bleiben Sie über alle aktuellen Entwicklungen informiert.

Auch als RSS Feed für Ihren RSS Feed Reader verfügbar.

Melden Sie sich hier für den Newsletter an:

Familienvater überlebt dank CARL.

Familienvater überlebt dank CARL. Ein plötzlicher Herztod kann jeden treffen. Nur etwa zehn Prozent der Patienten, die außerhalb eines Krankenhauses reanimiert wurden, überleben einen Herz-Kreislaufstillstand. Ein hoher Prozentsatz der Überlebenden leidet nach der Reanimation anhaltend unter gravierenden neurologischen Folgeschäden, die vor allem die Funktion des Gehirns betreffen. Die CARL Technologie wurde entwickelt, um mehr Menschen…

Weiterlesen >